Optinose announced that the phase III ReOpen1 clinical trial of Xhance (fluticasone propionate) Exhalation Delivery System in chronic sinusitis met both of its co-primary endpoints.
SinuSys Corp has announced receipt of the CE Mark for Vent-Os Sinus Dilation System, a low-pressure, self-expanding dilation device to...
The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score ≥ 10 at baseline.
Optinose announced the statistically significant benefits of Xhance (fluticasone propionate nasal spray) in the phase III ReOpen2 trial for both the symptoms co-primary endpoint and the CT scan co-primary endpoint.
Purpose of review: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common and heterogeneous inflammatory disease. The underlying epigenetic mechanisms and treatment of CRSwNP are partially understood.
Purpose of review: Staphylococcus aureus (S. aureus) is correlated with the development of persistent severe inflammatory disease of the upper airway including chronic rhinosinusitis with nasal polyps (CRSwNP). The presence of S. aureus is associated with atopic disease including allergic rhinitis and atopic dermatitis and is associated with poor outcomes.
Optinose , a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced the FDA has approved Xhance (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.
For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever), sinusitis.
Asthma is often associated with various comorbidities. The most frequently reported asthma comorbid conditions include rhinitis, sinusitis, gastroesophageal reflux disease, obstructive sleep apnea, hormonal disorders and psychopathologies.
The European Commission has granted Marketing Authorization (MA) for Incresync (alogliptin with pioglitazone), from Takeda, for the treatment of Type...